Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00608439
Other study ID # R21AT003668
Secondary ID R21AT003668
Status Completed
Phase Phase 2
First received January 28, 2008
Last updated November 9, 2012
Start date September 2007
Est. completion date August 2011

Study information

Verified date November 2012
Source Oregon Health and Science University
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this protocol is to investigate the safety, tolerability and effectiveness of CAST as a treatment for diabetic neuropathy. The primary outcome measure will be Total Neuropathic Symptom Score. Secondary outcomes will be neurological disability score, nerve conduction measurements and quantitative sensory testing. Statistical analyses will compare changes from baseline for CAST- and placebo-treated groups at both time points, compare effects of CAST at 6 and 12 months and, if numbers permit, compare doses.


Description:

This study is a clinical trial investigating the effect of an herbal supplement called CAST on diabetic neuropathy. CAST is an herb commonly used in traditional Indian medicine. In this tradition, it is used to increase memory, treat wounds and sores, skin diseases, and neurological conditions such as epilepsy. The herb has had growing popularity in the US; parts are sold as the dietary supplement "gotu kola" and used to improve blood circulation and help heal wounds. Unlike many other herbs, CAST has been extensively researched for many of the above conditions. The compounds found in CAST make it a very promising potential treatment for diabetic neuropathy because of its effect on blood circulation and growth of nerves.

Subjects will receive informed consent. They will then be screened for eligibility before entering the study. A medical history will be taken and subjects will have a neurological exam and vital signs taken. Subjects will have their blood drawn and will also give a urine sample for routine testing. Subjects will have an electrocardiogram (ECG) to check their heart. If a subject is a woman who is at risk of getting pregnant, she will have a urine pregnancy test.

If the subject is eligible for participation in the study, they will return for a total of nine additional study visits over the course of a year. Subjects will be randomly assigned to either receive the active supplement (CAST) or a placebo. A placebo is a pill that tastes, looks, and smells like the study drug but has no real medicine (or supplement) in it. Subjects have a 50% chance of receiving the active supplement. Neither the subject nor the study staff will know who receives the active supplement or the placebo. At visits 2, 7 and 10, subjects will get a comprehensive assessment of their neuropathy symptoms. This will include a Neurological Disability Score assessment, a nerve conduction study and a Quantitative Sensory Test.

Subjects enrolled in the study will begin taking their study pills at the beginning of week 1 of the study. During the first 12 weeks, subjects will be asked to increase their dose by one pill every four weeks. Therefore, they will increase the number of CAST or placebo pills from 60mg twice daily to 60mg four times daily, or the highest dose that does not cause side effects. Dr. Lou will monitor subjects for side effects of the study supplement. At each study visit, blood and urine samples will be taken for safety analysis, including liver and kidney function, and glucose control, and an ECG will be done to monitor heart activity. Subjects will be contacted by the study coordinator via phone call once per week during the first three months of the study. During the remainder of the study, they will be called once each month that they are not scheduled for an appointment. Treatment will conclude after one year.


Recruitment information / eligibility

Status Completed
Enrollment 43
Est. completion date August 2011
Est. primary completion date August 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

1. Type II diabetes that is being treated with diet, oral antidiabetic agents and/or insulin

2. stable glycemic control over the last 3 months

3. evidence of symptomatic symmetrical distal neuropathy

4. total symptom score of 4 or more

5. stable HbA1c level of less than 8.5 over last three months

Exclusion Criteria:

1. Smokers

2. Asymmetrical neuropathy of the trunk and proximal lower limbs

3. Presence of foot ulcers

4. Peripheral vascular disease (non-palpable foot pulses, intermittent claudication)

5. Myopathy

6. Causes of neuropathy other than diabetes

7. Participation in a study of any investigational drug for diabetic neuropathy within 3 months of the study

8. Use of any other product containing CA in the last 3 months

9. Starting to use antioxidants or Vitamin B within 1 month before the study

10. Severe concomitant diseases including neurological disease

11. Pregnancy, lactation or being of child-bearing age without birth control

12. HBA1c level higher than 8.5

13. Use of any experimental drugs in the three months prior to start of the study

14. Use of anti-coagulant therapy (heparin or coumarin based drugs)

15. A QTc of more than 500 ms at baseline ECG

16. Uncontrollable hypertension, defined as diastolic pressure greater than 110, and systolic pressure greater than 160

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Centella asiatica selected triterpenes (CAST)
Drug provided to subjects in 60 mg capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated dose from week 12 to 52.
Other:
Placebo
Placebo provided to subjects in 60 mg color-matched capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated "dose" from week 12 to 52.

Locations

Country Name City State
United States Oregon Health and Science University Portland Oregon

Sponsors (2)

Lead Sponsor Collaborator
Oregon Health and Science University National Center for Complementary and Integrative Health (NCCIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total Symptom Score one year No
Secondary Nerve Conduction Study one year No
Secondary Neurological Disability Test one year No
Secondary Quantitative Sensory Test one year No
See also
  Status Clinical Trial Phase
Completed NCT04025320 - The Effect of Intraneural Facilitation Therapy on Diabetic Patients With Peripheral Neuropathy N/A
Completed NCT02659007 - Less Neuropathy After Yoga- Managing Diabetic Neuropathy With Yoga Phase 1
Completed NCT01953757 - A Nutritional Intervention for Diabetic Neuropathy (WCCR-DN2) N/A
Completed NCT01707979 - NIR- and Multifrequent Impedance Spectroscopy on the Skin in Type 1 Diabetes N/A
Completed NCT00576277 - Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain Phase 1/Phase 2
Completed NCT00235443 - A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy Phase 2/Phase 3
Completed NCT00830011 - Cognitive Behavioral Therapy for Painful Diabetic Neuropathy N/A
Completed NCT00931879 - Lovaza® and Microvascular Function in Type 2 Diabetes Phase 4
Completed NCT00101426 - Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy Phase 3
Completed NCT00190970 - The Effect of Ruboxistaurin on Small Fiber Function Phase 2
Completed NCT00238550 - Study of CBME in the Relief of Painful Diabetic Neuropathy Phase 2
Completed NCT05573685 - Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMoâ„¢ Component Training N/A
Recruiting NCT02341261 - Activity for Diabetic Polyneuropathy N/A
Completed NCT01822925 - Study of DA-9801 to Treat Diabetic Neuropathy Phase 2
Completed NCT01690962 - A Nutritional Intervention for Diabetic Neuropathy N/A
Terminated NCT00993018 - A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy Phase 2
Withdrawn NCT02315235 - The Peripheral Mobilized Mononuclear Cell-based Therapy in Patient With Diabetic Neuropathy N/A
Completed NCT00496457 - Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy Phase 2
Recruiting NCT02606747 - The Balance Control Mechanism of DPN Patients N/A
Completed NCT02068027 - Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy Phase 2